QDEL

QUIDELORTHO CORP

Healthcare | Small Cap

$0.23

EPS Forecast

$620.5

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Quidel Q1 2022: The Rapid Immunoassay Engine Keeps Purring, But For How Long?

Ticker: QDEL • EPS (GAAP) $11.31; EPS (non-GAAP) $11.66; Revenue: $1,002.3 million. Tracking revenue forecast and EPS consensus angles will be key as investors parse a quarter driven by rapid-diagnostics demand.

Overview: A quarter shaped by COVID-19 testing demand

Quidel Corporation, listed as QDEL, reported first-quarter 2022 results showing a 167% jump in total revenues to $1,002.3 million from $375.3 million a year earlier. The surge was powered by rapid tests and COVID-19 product sales, which totaled $836.1 million, up 211% year over year. The company noted a modest negative currency impact of about - $1.0 million.

The quarter's dynamics center on a COVID-19 testing wave, with a broader product mix that includes Cardiometabolic Immunoassay and Molecular Diagnostic Solutions. The document shows a strong top line while signaling how much the mix depends on external demand for rapid tests.

Drivers of Growth and Product Mix

  • Rapid Immunoassay revenue surged to $892.8 million, up by $655.1 million, led by QuickVue At-Home OTC COVID-19 tests and Sofia Influenza tests.
  • COVID-19 product sales accounted for the bulk of the gains: $836.1 million in the quarter, up 211% from prior year.
  • Cardiometabolic Immunoassay revenue was $50.2 million, down from $66.6 million in Q1 2021, reflecting the impact of the Beckman Coulter agreement for the B-type Natriuretic Peptide assay business. Under that arrangement, $16.8 million of revenue was recorded in Q1 2022 vs. $33.5 million in Q1 2021.
  • Molecular Diagnostic Solutions revenue stood at $46.0 million; the release text truncates with “Specialized Diagno,” leaving some details to be filled in by management’s full report.

Earnings and Per-Share Appearance

The quarter produced a GAAP EPS of $11.31 per diluted share and a non-GAAP EPS of $11.66 per diluted share, underscoring how a heavy top-line contribution can flow through to earnings on the right mix and currency backdrop.

The report does not provide a direct earnings surprise comparison to a stated EPS consensus within the excerpt, but the scale of the top-line surge will invite scrutiny of Street estimates in the upcoming cycle. Investors typically watch whether actual EPS outpaced consensus and how that aligns with the revenue trajectory.

Outlook and Sector Implications

The quarter’s strength is inseparable from demand for rapid diagnostics, including at-home COVID-19 tests. If this demand proves durable, Quidel could sustain elevated revenue levels beyond the near term. However, execution risk remains if testing volumes temper or if competition intensifies, potentially compressing margins or altering the product mix.

The Beckman Coulter arrangement illustrates how partnerships can materially shift revenue composition—an important consideration for peers evaluating go-to-market structures and collaboration economics. The lack of explicit forward revenue forecast in the excerpt means guidance may come in subsequent releases; investors will likely infer trajectory from the current mix, product uptake, and any commentary on test utilization trends.

Implications for Peers and the Diagnostic Sector

Quidel’s results set a benchmark for rapid-diagnostics exposure within a multi-product portfolio. Sector peers—both those with heavy rapid-immunoassay exposure and those with more balanced portfolios—will parse whether the Q1 surge is a temporary pandemic tail or a sign of more persistent demand in respiratory and influenza testing. Expect discussions around EPS consensus alignment and revenue forecast revisions as companies articulate the durability of their own product ramps.

Closing Take: A Quarter with a Big Test in It

Quidel’s Q1 2022 narrative reads like a diagnostic company leaning into a favorable, if perhaps episodic, demand cycle. The EPS strength mirrors a robust top line, but the real question for investors will be how much of this is a structural shift versus a pandemic-fueled spike. The coming quarters will need to answer whether the revenue forecast, and the EPS consensus around it, stabilizes as the market for rapid tests evolves and as partnerships like Beckman Coulter reshape the firm’s long-run mix.

In the meantime, the sector’s gaze will stay fixed on revenue forecast trajectories and the staying power of the rapid-immunoassay engine. If the pace sustains, Quidel could offer a model for how to monetize a surge responsibly; if not, it may simply remind us that in diagnostics, timing is the true variable.